Macrae J, Hyde P. HHS Launches Multi-pronged Effort to Combat Opioid Abuse. Washington, DC: U.S. Department of Health & Human Services; Jul 27, 2015. [Accessed August 8, 2016]. http://www​.hhs.gov/blog​/2015/07/27/hhs-launches-multi-pronged-effort-combat-opioid-abuse.html.

American Psychiatric Association. The diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013.

Center for Behavioral Health Statistics and Quality. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; Sep, 2015. [Accessed June 29, 2016]. (Prepared by RTI International under Contract No. HHSS283201300001C.) HHS Publication No. SMA 15-4927. http://www​.samhsa.gov​/data/sites/default​/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014​.pdf.

Overdose Death Rates. Bethesda, MD: National Institute on Drug Abuse; Feb, 2015. [Accessed August 8, 2016]. http://www​.drugabuse​.gov/related-topics/trends-statistics​/overdose-death-rates.

Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008 Aug 31;138(2):440–9. [PMC free article: PMC2668925] [PubMed: 18547726] [CrossRef]

Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1166–75. [PMC free article: PMC3280087] [PubMed: 19718704] [CrossRef]

Volkow ND. America’s Addiction to Opioids: Heroin and Prescription Drug Abuse. Bethesda, MD: National Institute on Drug Abuse; May 14, 2014. [Accessed November 3, 2015]. https://www​.drugabuse​.gov/about-nida/legislative-activities​/testimony-to-congress​/2015/americas-addiction-to-opioids-heroin-prescription-drug-abuse#_ftn5.

Chou R, Deyo R, Devine B, et al. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Rockville, MD: Agency for Healthcare Research and Quality; Sep, 2014. Evidence Report/Technology Assessment No. 218. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 14-E005-EF.

Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015 Feb 17;162(4):276–86. [PubMed: 25581257] [CrossRef]

Cicero TJ, Ellis MS, Surratt HL, et al. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014 Jul 1;71(7):821–6. [PubMed: 24871348] [CrossRef]

Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates. Subst Abuse Rehabil. 2015;6:83–91. [PMC free article: PMC4548725] [PubMed: 26316838] [CrossRef]

Behavioral Health Coordinating Committee Prescription Drug Abuse Subcommittee. Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities. Washington, DC: U.S. Department of Health & Human Services; 2013. [Accessed June 29, 2016]. http://www​.cdc.gov/drugoverdose​/pdf/hhs_prescription​_drug_abuse_report_09​.2013.pdf.

National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998 Dec 9;280(22):1936–43. [PubMed: 9851480]

Friedmann PD, Schwartz RP. Just call it “treatment” Addiction Science & Clinical Practice. 2012;7:10. [PMC free article: PMC3507631] [PubMed: 23186149] [CrossRef]

Saitz R. Things that Work, Things that Don’t Work, and Things that Matter--Including Words. J Addict Med. 2015 Nov–Dec;9(6):429–30. [PubMed: 26517322] [CrossRef]

Department of Health and Human Services Substance Abuse and Mental Health Services Administration. Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (Short Title - MAT-PDOA) Initial Announcement. 2016. [Accessed April 28, 2016]. http://www​.samhsa.gov​/sites/default/files​/grants/pdf/ti-16-014.pdf.

Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. [PMC free article: PMC10617756] [PubMed: 24500948] [CrossRef]

Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209. [PMC free article: PMC7097731] [PubMed: 19588333] [CrossRef]

National Institute on Drug Abuse. Medication-Assisted Treatment for Opioid Addiction. 2012. [Accessed April 4, 2016]. https://www​.drugabuse​.gov/sites/default/files​/tib_mat_opioid.pdf.

Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: U.S. Substance Abuse and Mental Health Services Administration; 2005. [Accessed June 29, 2016]. (SAMHSA/CSAT Treatment Improvement Protocol (TIP) Series, No. 43). HHS Publication No. (SMA) 12-4214. http://www​.ncbi.nlm.nih​.gov/books/NBK64164​/pdf/Bookshelf_NBK64164.pdf. [PubMed: 22514849]

The White House. Addressing Prescription Drug Abuse and Heroin Use [Presidential Memorandum]. Office of the Press Secretary; 2015. [Accessed August 8, 2016]. https://www​.whitehouse​.gov/the-press-office​/2015/10/21/presidential-memorandum-addressing-prescription-drug-abuse-and-heroin.

Center for Substance Abuse Treatment. Executive Summary. Rockville, MD: U.S. Substance Abuse and Mental Health Services Administration; 2004. [Accessed June 29, 2016]. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. (Substance Abuse and Mental Health Services Administration Treatment Improvement Protocol (TIP) Series, No. 40). http://www​.ncbi.nlm.nih​.gov/books/NBK64243/

Jones CM, Campopiano M, Baldwin G, et al. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015 Aug;105(8):e55–63. [PMC free article: PMC4504312] [PubMed: 26066931] [CrossRef]

Rosenblatt RA, Andrilla CH, Catlin M, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015 Jan–Feb;13(1):23–6. [PMC free article: PMC4291261] [PubMed: 25583888] [CrossRef]

Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011 Mar;5(1):21–7. [PMC free article: PMC3045214] [PubMed: 21359109] [CrossRef]

Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010 Sep;25(9):936–41. [PMC free article: PMC2917666] [PubMed: 20458550] [CrossRef]

Providers’ Clinical Support System for Medication Assisted Treatment [PCSSMAT] [Accessed October 30, 2015]. http://pcssmat​.org/

Substance Abuse and Mental Health Services Administration. Drug Addiction Treatment Act of 2000. [Accessed June 24, 2016]. http:​//buprenorphine​.samhsa.gov/titlexxxv.html.

Chen H. Increasing Access to Opioid Addiction Treatment. 2014. [Accessed August 8, 2016]. http://www​.leg.state​.vt.us/reports/2014ExternalReports​/299315.pdf.

Patient-Centered Primary Care Collaborative. Vermont Hub and Spokes Health Homes Statewide. 2015. [Accessed August 8, 2016]. https://www​.pcpcc.org​/initiative/vermont-hub-and-spokes-health-homes.

Vermont Agency of Human Services. Integrated Treatment Continuum for Substance Use Dependence “Hub/Spoke” Initiative-Phase 1: Opioid Dependence. 2012. [Accessed August 8, 2016]. http://www​.healthvermont​.gov/adap/documents​/HUBSPOKEBriefingDocV122112.pdf.

Alliance of Community Health Plans. Vermont Health Homes for Opioid Addiction Hub & Spoke Program Overview. 2013. [Accessed August 8, 2016]. http://www​.achp.org/wp-content​/uploads/Vermont-Health-Homes-for-Opiate-Addiction-September-2013.pdf.

Stoller K. Innovative Practices in Medication Assisted Treatment and Primary Care Coordination: Linking Buprenorphine Prescribers with Opioid Treatment Programs: Expand Capacity while Improving Quality. 2015. [Accessed August 8, 2016]. http://www​.atforum.com​/pdf/CoOPtalkforONDCP​_SAMHSAAug2015Stoller.pdf.

Stoller K. A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers. Addict Sci Clin Pract. 2015;10(1):1. [CrossRef]

Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addiction. 2008 Mar–Apr;17(2):116–20. [PubMed: 18393054] [CrossRef]

Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006 Jul 27;355(4):365–74. [PubMed: 16870915]

Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse. 2002;28(2):231–41. [PubMed: 12014814]

Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011 Mar 14;171(5):425–31. [PMC free article: PMC3059544] [PubMed: 21403039] [CrossRef]

Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007 Feb;22(2):171–6. [PMC free article: PMC1824722] [PubMed: 17356982]

LaBelle CT, Han SC, Bergeron A, et al. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers. J Subst Abuse Treat. 2016 Jan;60:6–13. [PMC free article: PMC4682362] [PubMed: 26233698] [CrossRef]

Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S22–32. [PMC free article: PMC3263431] [PubMed: 21317590] [CrossRef]

Fiellin DA. Buprenorphine Treatment in HIV Primary Care: The HRSA SPNS BHIVES Initiative. 2010. [Accessed March 30, 2016]. http:​//buprenorphine​.samhsa.gov/bwns/2010_presentations_pdf​/19_Fiellin_2_508.pdf.

Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S33–8. [PMC free article: PMC3863630] [PubMed: 21317592] [CrossRef]

Korthuis PT, Fiellin DA, Fu R, et al. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S83–90. [PMC free article: PMC3066190] [PubMed: 21317600] [CrossRef]

Korthuis PT, Tozzi MJ, Nandi V, et al. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S39–45. [PMC free article: PMC3073082] [PubMed: 21317593] [CrossRef]

Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med. 2010 Jun 1;152(11):704–11. [PMC free article: PMC2886293] [PubMed: 20513828] [CrossRef]

Raymond SC. Integrating Buprenorphine Opioid Abuse Treatment Into HIV Primary Care: Webinar Series. SlideShare; 2012. [Accessed August 8, 2016]. http://www​.slideshare​.net/SarahCookRaymond​/buprenorphine-therapy-in-the-hiv-pruma.

Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006 Dec 15;43(Suppl 4):S184–90. [PubMed: 17109305]

TARGET Center. BEEHIVE Buprenorphine Program Tools. University of California; San Franscisco: 2009. [Accessed August 8, 2016]. https://www​.careacttarget​.org/library/beehive-buprenorphine-program-tools.

Weiss L, Egan JE, Botsko M, et al. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S7–13. [PubMed: 21317598] [CrossRef]

Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S68–75. [PubMed: 21317597] [CrossRef]

HIV/AIDS Bureau Special Projects of National Significance Program. Integrating Buprenorphine Therapy Into HIV Primary Care Settings. Rockville, MD: US Department of Health & Human Services, Health Resources and Services Administration; 2011. [Accessed April 7, 2016]. http://hab​.hrsa.gov/abouthab​/files/hab_spns​_buprenorphine_monograph.pdf.

Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387–402. [PubMed: 22820792] [CrossRef]

Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care Panel. Ann Intern Med. 2012 Jun 5;156(11):817–33. w-284, w-5, w-6, w-7, w-8, w-9, w-90, w-91, w-92, w-93, w-94. [PMC free article: PMC4044043] [PubMed: 22393036] [CrossRef]

Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016 Jan–Mar;37(1):20–4. [PMC free article: PMC4873719] [PubMed: 26848803] [CrossRef]

Project ECHO. ECHO Access Opioid Use Disorder Treatment Guideline Opioid Abuse and Addiction Management Protocol. 2014. [Accessed August 8, 2016]. http://echo​.unm.edu/wp-content​/uploads/2014​/10/Opioid-Abuse-and-Addiction-Management-Protocol.pdf.

Pupillo J. Project ECHO Trains, Empowers New Mexico FPs to Provide Subspecialty Care. American Academy of Family Physicians; 2014. [Accessed August 8, 2016]. http://www​.aafp.org/news​/chapter-of-the-month​/20140930nmafp-chapspot.html.

Mann C, Frieden T, Hyde PS, et al. Medication Assisted Treatment for Substance Use Disorders [Informational Bulletin]. 2014. [Accessed March 30, 2016]. https://www​.medicaid​.gov/Federal-Policy-Guidance​/Downloads/CIB-07-11-2014.pdf.

Moses K, Klebonis J. Strategies CfHC. Designing Medicaid Health Homes for Individuals with Opioid Dependency: Considerations for States [Brief]. Center for Medicare and Medicaid Services; 2015. [Accessed March 30, 2016]. https://www​.medicaid​.gov/state-resource-center​/medicaid-state-technical-assistance​/health-homes-technical-assistance​/downloads​/health-homes-for-opiod-dependency.pdf.

Oregon Pain Guidance. Pain Management Guidance and Tools for Patients, Families, and Healthcare Professionals. 2016. [on October 20, 2016]. Accessed at www​.oregonpainguidance.org.

D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1636–44. [PMC free article: PMC4527523] [PubMed: 25919527] [CrossRef]

Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014 Aug;174(8):1369–76. [PMC free article: PMC4811188] [PubMed: 25090173] [CrossRef]

Pecoraro A, Ma M, Woody GE. The science and practice of medication-assisted treatments for opioid dependence. Subst Use Misuse. 2012 Jun–Jul;47(8–9):1026–40. [PubMed: 22676570] [CrossRef]

Shanahan CW, Beers D, Alford DP, et al. A Transitional Opioid Program to Engage Hospitalized Drug Users. J Gen Intern Med. 2010;25(8):803–8. [PMC free article: PMC2896583] [PubMed: 20237960] [CrossRef]

Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320–31. [PMC free article: PMC3073631] [PubMed: 21142534] [CrossRef]

Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005 Jul;79(1):1–10. [PubMed: 15943939]

Conrad C, Bradley HM, Broz D, et al. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorhone -- Indiana 2015. MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443–4. [PMC free article: PMC4584812] [PubMed: 25928470]

LifeSpring Health Systems. About Us: Locations. [Accessed August 8, 2016]. http://www​.lifespringhealthsystems​.org/about-us/locations/

Chaudhry AA, Botsko M, Weiss L, et al. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S14–21. [PubMed: 21317589] [CrossRef]

Cheever LW, Kresina TF, Cajina A, et al. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S3–6. [PubMed: 21317591] [CrossRef]

Egan JE, Netherland J, Gass J, et al. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S46–53. [PubMed: 21317594] [CrossRef]

Finkelstein R, Netherland J, Sylla L, et al. Policy Implications of Integrating Buprenorphine/Naloxone Treatment and HIV Care. J Acquir Immune Defic Syndr. 2011;56:S98–S104. [PubMed: 21317602] [CrossRef]

Friedland G, Vlahov D. Integration of buprenorphine for substance-abuse treatment by HIV care providers. J Acquir Immune Defic Syndr. 2011 Mar;56(Suppl 1):S1–S2. [PubMed: 21317588] [CrossRef]

Lum PJ, Little S, Botsko M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S91–7. [PubMed: 21317601] [CrossRef]

Schackman BR, Leff JA, Botsko M, et al. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S76–82. [PMC free article: PMC3270565] [PubMed: 21317599] [CrossRef]

Sullivan LE, Botsko M, Cunningham CO, et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S54–61. [PMC free article: PMC3065971] [PubMed: 21317595] [CrossRef]

Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr. 2011 Mar 1;56(Suppl 1):S62–7. [PubMed: 21317596] [CrossRef]

Executive Office of Health and Human Services (EOHHS). Get Help: Types of Treatment. 2015. [Accessed August 8, 2016]. http://www​.mass.gov/eohhs​/gov/departments​/dph/stop-addiction​/get-help-types-of-treatment.html.

Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013 Jul 1;131(1–2):127–35. [PMC free article: PMC3674170] [PubMed: 23332439] [CrossRef]

Westat, The AVISA Group. The SAMHSA Evaluation of the Impact of the DATA Waiver Program Summary Report. 2006. [Accessed April 7, 2016]. http://www​.samhsa.gov​/sites/default/files​/programs_campaigns​/medication_assisted​/evaluation-impact-data-waiver-program-summary.pdf.

SAMHSA: Substance Abuse and Mental Health Services Administration. Physician and Program Data. 2015. [Accessed April 7, 2016]. http://www​.samhsa.gov​/programs-campaigns​/medication-assisted-treatment​/physician-program-data.

Lines L. State-level influences on buprenorphine utilization: Variations in opioid addiction treatment. APHA: Amercian Public Health Association; 2011. [Accessed April 7, 2016]. https://apha​.confex.com​/apha/139am/webprogram/Paper252544​.html.

Dick AW, Pacula RL, Gordon AJ, et al. Growth in nuprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Aff (Millwood). 2015 Jun;34(6):1028–34. [PMC free article: PMC4743254] [PubMed: 26056209] [CrossRef]

Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015 Jan;48(1):104–11. [PMC free article: PMC4420477] [PubMed: 25218919] [CrossRef]

Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015 Sep;93(3):561–83. [PMC free article: PMC4567853] [PubMed: 26350930] [CrossRef]

Knudsen HK, Lofwall MR, Havens JR, et al. States’ implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug Alcohol Depend. 2015 Dec 1;157:36–43. [PMC free article: PMC4663127] [PubMed: 26483356] [CrossRef]

Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008 Sep;23(9):1393–8. [PMC free article: PMC2518016] [PubMed: 18592319] [CrossRef]

Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014 Mar–Apr;12(2):128–33. [PMC free article: PMC3948759] [PubMed: 24615308] [CrossRef]

Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014 Apr;71(4):359–60. [PubMed: 24500040] [CrossRef]

Molfenter T, Sherbeck C, Zehner M, et al. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. Subst Abuse Treat Prev Policy. 2015;10:13. [PMC free article: PMC4395880] [PubMed: 25884206] [CrossRef]

DeFlavio JR, Rolin SA, Nordstrom BR, et al. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019. [PubMed: 25651434]

Arfken CL, Johanson CE, di Menza S, et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat. 2010 Sep;39(2):96–104. [PubMed: 20598829] [CrossRef]

Providers’ Clinical Support System for Medication Assisted Treatment (PCSS MAT). PCSS MAT Training: How to prepare for a visit from the Drug Enforcement Agency (DEA) regarding buprenorphine prescribing. [Accessed August 3, 2016]. http://pcssmat​.org/wp-content​/uploads/2014​/02/FINAL-How-to-Prepare-for-a-DEA-Inspection.pdf.

Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Subst Abus. 2016 Jan–Mar;37(1):63–9. [PMC free article: PMC4801690] [PubMed: 26566761] [CrossRef]

Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;(10):Cd004147. [PubMed: 21975742] [CrossRef]

Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014 Dec;82(6):964–72. [PMC free article: PMC4244262] [PubMed: 25090043] [CrossRef]

Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013 Jan;126(1):74.e11–7. [PMC free article: PMC3621718] [PubMed: 23260506] [CrossRef]

Moore BA, Barry DT, Sullivan LE, et al. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med. 2012 Sep;6(3):205–11. [PMC free article: PMC3419276] [PubMed: 22614936] [CrossRef]

Galanter M, Dermatis H, Glickman L, et al. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat. 2004 Jun;26(4):313–8. [PubMed: 15182896]

Tetrault JM, Moore BA, Barry DT, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat. 2012 Dec;43(4):433–9. [PubMed: 22938914] [CrossRef]

Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011 Dec;68(12):1238–46. [PMC free article: PMC3470422] [PubMed: 22065255] [CrossRef]

Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015 May 1;150:112–9. [PMC free article: PMC4407806] [PubMed: 25818060] [CrossRef]

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349(10):949–58. [PubMed: 12954743]

Lintzeris N, Ritter A, Panjari M, et al. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addictions. 2004;13(Suppl 1):S29–41. [PubMed: 15204674]

Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013 Dec;108(12):2141–9. [PMC free article: PMC4669043] [PubMed: 23919595] [CrossRef]

Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010 Oct 13;304(14):1576–83. [PubMed: 20940383] [CrossRef]

Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):Cd001333. [PMC free article: PMC7045778] [PubMed: 21491383] [CrossRef]

Lobmaier P, Kornor H, Kunoe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD006140. [PubMed: 18425938] [CrossRef]

Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006 Feb;63(2):210–8. [PMC free article: PMC4200530] [PubMed: 16461865]

Larney S, Gowing L, Mattick RP, et al. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev. 2014 Mar;33(2):115–28. [PubMed: 24299657] [CrossRef]

Lobmaier PP, Kunoe N, Gossop M, et al. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011 Dec;17(6):629–36. [PMC free article: PMC6493794] [PubMed: 21554565] [CrossRef]

Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012 Sep;69(9):973–81. [PMC free article: PMC3614358] [PubMed: 22945623] [CrossRef]

Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009 Oct;66(10):1108–15. [PubMed: 19805701] [CrossRef]

Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011 Apr 30;377(9776):1506–13. [PubMed: 21529928] [CrossRef]

Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013 Sep;108(9):1628–37. [PubMed: 23701526] [CrossRef]

Carrieri PM, Michel L, Lions C, et al. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS ONE [Electronic Resource] 2014;9(11):e112328. [PMC free article: PMC4231094] [PubMed: 25393311] [CrossRef]

Roux P, Michel L, Cohen J, et al. Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial. BMC Public Health. 2012;12:488. [PMC free article: PMC3528472] [PubMed: 22741944] [CrossRef]

Fiellin DA, O’Connor PG, Chawarski M, et al. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001 Oct 10;286(14):1724–31. [PubMed: 11594897]

King VL, Kidorf MS, Stoller KB, et al. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abuse Treat. 2006 Dec;31(4):385–93. [PubMed: 17084792]

Ferri M, Minozzi S, Bo A, et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013;6:Cd009879. [PubMed: 23740540] [CrossRef]

Minozzi S, Amato L, Bellisario C, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318. [PubMed: 24366859] [CrossRef]

Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008 Nov 5;300(17):2003–11. [Erratum appears in JAMA. 2009 Feb 25;301(8):830], [Erratum appears in JAMA. 2013 Apr 10;309(14):1461] [PMC free article: PMC2610690] [PubMed: 18984887] [CrossRef]

Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):Cd004145. [PubMed: 21833948] [CrossRef]

Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial. Drug Alcohol Depend. 2008 Apr 1;94(1–3):281–4. [PubMed: 18164145] [CrossRef]

Gossop M, Marsden J, Stewart D, et al. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend. 2000 Nov 1;60(3):275–86. [PubMed: 11053762]

Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5):CD011117. [PubMed: 27157143]

Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescent. Cochrane Database Syst Rev. 2009;(2):CD007210. [PubMed: 19370679] [CrossRef]

Rahimi-Movaghar A, Amin-Esmaeili M, Hefazi M, et al. Pharmacological therapies for maintenance treatments of opium dependence. Cochrane Database Syst Rev. 2013;1:Cd007775. [PubMed: 23440817] [CrossRef]

McLellan AT, Starrels JL, Tai B, et al. Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group. Public Health Rev. 2014 Jan;35(2) [PMC free article: PMC4643942] [PubMed: 26568649]

Bassuk EL, Hanson J, Greene RN, et al. Peer-Delivered Recovery Support Services for Addictions in the United States: A Systematic Review. J Subst Abuse Treat. 2016 Apr;63:1–9. [PubMed: 26882891] [CrossRef]

Carroll KM, Ball SA, Martino S, et al. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry. 2008 Jul;165(7):881–8. [PMC free article: PMC2562873] [PubMed: 18450927] [CrossRef]

Carroll KM, Ball SA, Martino S, et al. Enduring effects of a computer-assisted training program for cognitive behavioral therapy: a 6-month follow-up of CBT4CBT. Drug Alcohol Depend. 2009 Feb 1;100(1–2):178–81. [PMC free article: PMC2742309] [PubMed: 19041197] [CrossRef]

DiPaula BA, Menachery E. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc. 2015 Mar–Apr;55(2):187–92. [PubMed: 25749264] [CrossRef]

Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health’s office-based Buprenorphine Pilot Program. J Psychoactive Drugs. 2011 Apr–Jun;43(2):136–45. [PubMed: 21858959]

Schmidt LA, Rieckmann T, Abraham A, et al. Advancing recovery: implementing evidence-based treatment for substance use disorders at the systems level. J Stud Alcohol Drugs. 2012 May;73(3):413–22. [PMC free article: PMC3594882] [PubMed: 22456246]

Cottrill CB, Matson SC. Medication-assisted treatment of opioid use disorder in adolescents and young adults. Adolesc Med. 2014 Aug;25(2):251–65. [PubMed: 27132312]

Alanis-Hirsch K, Croff R, Ford JH 2nd, et al. Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. J Subst Abuse Treat. 2016 Mar;62:68–73. [PMC free article: PMC4724460] [PubMed: 26654934] [CrossRef]

Alford DP, German JS, Samet JH, et al. Primary Care Patients with Drug Use Report Chronic Pain and Self-Medicate with Alcohol and Other Drugs. J Gen Intern Med. 2016 May;31(5):486–91. [PMC free article: PMC4835374] [PubMed: 26809204] [CrossRef]

Barry DT, Savant JD, Beitel M, et al. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addiction. 2013 May–Jun;22(3):212–7. [PMC free article: PMC3641684] [PubMed: 23617861] [CrossRef]

Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014 Jul;15(7):1171–8. [PubMed: 24995716] [CrossRef]

Schackman BR, Leff JA, Polsky D, et al. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012 Jun;27(6):669–76. [PMC free article: PMC3358393] [PubMed: 22215271] [CrossRef]

Mohlman MK, Tanzman B, Finison K, et al. Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont. J Subst Abuse Treat. 2016 Aug;67:9–14. [PubMed: 27296656] [CrossRef]

Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014 Jan;46(1):43–51. [PMC free article: PMC3839618] [PubMed: 24060350] [CrossRef]

Stein MD, Risi MM, Bailey GL, et al. Linkage to primary care for persons first receiving injectable naltrexone during inpatient opioid detoxification. J Subst Abuse Treat. 2016 May;64:44–6. [PMC free article: PMC4818184] [PubMed: 26920817] [CrossRef]

Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice--a summary report (1983-1998). Mt Sinai J Med. 2000 Oct–Nov;67(5–6):388–97. [PubMed: 11064489]

Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care. An implementation evaluation. J Gen Intern Med. 2005 Apr;20(4):344–9. [PMC free article: PMC1490098] [PubMed: 15857492]

Harris KA Jr, Arnsten JH, Joseph H, et al. A 5-year evaluation of a methadone medical maintenance program. J Subst Abuse Treat. 2006 Dec;31(4):433–8. [PMC free article: PMC2692058] [PubMed: 17084798]

National Institute on Drug Abuse. Principles of adolescent substance use disorder treatment: a research-based guide. 2014. [Accessed June 24, 2016]. https://www​.drugabuse​.gov/sites/default/files​/podata_1_17_14.pdf.

Wu L-T, Blazer DG, Li T-K, et al. Treatment use and barriers among adolescents with prescription opioid use disorders. Addict Behav. 2011 Aug 07;36(12):1233–9. [PMC free article: PMC3179790] [PubMed: 21880431] [CrossRef]

Ober A, Watkins K, Hunter S, et al. An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol. 2015. [Accessed April 7, 2016]. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t] http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC4432875/ [PMC free article: PMC4432875] [PubMed: 25951953]

Bogenschutz M. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2000. [Accessed April 7. 2016]. Comparing interventions for opioid dependent patients presenting in medical emergency departments. [cited 2016 Jun 30] https://clinicaltrials.gov/ct2/show/NCT02586896. NLM Identifier: NCT02586896.

Stein M. Linking opioid-dependent patients from inpatient detoxification to primary care. [Accessed June 30, 2016]. https://wwwcf​.nlm.nih​.gov/hsr_project/view_hsrproj_record​.cfm?NLMUNIQUE_ID​=20132453&SEARCH​_FOR=(((​%22primary%20care​%22))%20AND(buprenorphine))​%20OR(naltrexone) NLM Identifier: NCT01751789.

Fox A. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2000. Buprenorphine group medical visits in primary care. [cited 2016 Jun 30] https://clinicaltrials.gov/ct2/show/NCT02526212. NLM Identifier: NCT02526212.

Sigmon S. Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access. 2015. [Accessed June 30, 2016]. [Study: NCT02360007] https:​//trialbulletin​.com/lib/entry/ct-02360007. NLM Identifier: NCT02360007.

Department of Health and Human Services. Funding Opportunity: Increasing Access to Medication-Assisted Treatment (MAT) in Rural Primary Care Practices (R18). 2015. [Accessed June 24, 2016]. http://grants​.nih.gov​/grants/guide/rfa-files/RFA-HS-16-001​.html.

Watkins K. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US); 2000. [Accessed April 7, 2016]. Integrated collaborative care for substance use disorders. [cited 2016 Jun 30] https://clinicaltrials.gov/ct2/show/NCT01810159. NLM Identifier: NCT01810159.